Global Orphan Drugs Market 2014-2018

Global Orphan Drugs Market 2014-2018

Category : Pharmaceuticals
Published On : January  2014
Pages : 66



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

TechNavio's analysts forecast the Global Orphan Drugs market to grow at a CAGR of 5.67 percent over the period 2013-2018. One of the key factors contributing to this market growth is the shorter development timelines. The Global Orphan Drugs market has also been witnessing the growing awareness of orphan drugs. However, the high cost of drug development could pose a challenge to the growth of this market. 
TechNavio's report, the Global Orphan Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Orphan Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space are Novartis AG, F. Hoffmann-La Roche Ltd., Celgene Corp., Pfizer Inc., and Sanofi S.A.
Other vendors mentioned in the report are Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals Inc., Amgen Inc., Baxter International Inc., Biogen Idec Inc., Bristol-Myers-Squibb Co., GlaxoSmithKline plc, Eli Lilly & Co., Merck KGaA, Novo Nordisk A/S, Onyx Pharmaceuticals Inc., Shire plc, and Vertex Pharmaceuticals Inc.
Key questions answered in this report: 
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

 

 

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report


03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape


06.1 Market Overview

06.2 Market Size and Forecast

06.3 Global Biologics Orphan Drugs Market

Market Size and Forecast

06.4 Global Non-Biologic Orphan Drugs Market

Market Size and Forecast

06.5 Five Forces Analysis

07. Market Segmentation by Product

08. Geographical Segmentation

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape


16.1 Competitive Scenario

16.1.1 Key News

16.1.2 Mergers and Acquisitions

16.2 Market Share Analysis 2012

16.3 Other Prominent Vendors

17. Key Vendor Analysis

17.1 Novartis AG

17.1.1 Business Overview

17.1.2 Business Segmentation

17.1.3 Key Information

17.1.4 SWOT Analysis

17.2 F. Hoffmann La Roche Ltd.

17.2.1 Business Overview

17.2.2 Business Segmentation

17.2.3 Key Information

17.2.4 SWOT Analysis

17.3 Celgene Corp.

17.3.1 Business Overview

17.3.2 Key Information

17.3.3 SWOT Analysis

17.4 Pfizer Inc.

17.4.1 Business Overview

17.4.2 Key Information

17.4.3 SWOT Analysis

17.5 Sanofi S.A.

17.5.1 Business Overview

17.5.2 Business Segmentation

17.5.3 Key Information

17.5.4 SWOT Analysis

18. Other Reports in this Series



List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global Orphan Drugs Market 2013-2018 (US$ billion)

Exhibit 3: Global Biologics Orphan Drugs Market 2013-2018 (US$ billion)

Exhibit 4: Global Non-Biologic Orphan Drugs Market 2013-2018 (US$ billion)

Exhibit 5: Global Orphan Drugs Market Segmentation 2013-2018 (by percentage)

Exhibit 6: Global Orphan Drugs Market Segmentation by Product

Exhibit 7: Global Orphan Drugs Market Segmentation 2013

Exhibit 8: Global Orphan Drugs Market by Geographical Segmentation 2013

Exhibit 9: FDA Approval Time: Orphan vs. Non-Orphan (months)

Exhibit 10: Phase Three Trial Length (yrs) Orphan vs. Non-Orphan

Exhibit 11: Global Orphan Drugs Market by Vendor Segmentation 2013

Exhibit 12: Global Orphan Drugs Market by Vendor Segmentation 2018

Exhibit 13: Global Orphan Drug Sales: Top 20 companies 2013-2018

Exhibit 14: Global USA and EU Orphan Designations per year (2009-2012)

Exhibit 15: Business Segmentation of Novartis AG

Exhibit 16: Business Segmentation of F. Hoffmann La Roche Ltd.

Exhibit 17: Business Segmentation of Sanofi S.A.



 


Enquiry Before Buy
image
Can´t read the image ? refresh here.